Key facts
- Notable investors include Beijing Zhongguancun Collaborative Innovation Investment Fund Management, Grand Capital (), Shanghai Shanda Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Taihao Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Taihao Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Taihao Biotech
Developer of point-of-care testing (POCT) systems designed for microfluidic molecular diagnostics. The company develops nucleic acid detection kits based on centrifugal microfluidic chips, committing to providing more accurate, faster, more convenient and cheaper in vitro diagnostic methods.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- taihaobiotech.com.cn/
- Ownership
- Privately Held (backing)
Taihao Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Taihao Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Taihao Biotech in its N-PORT filings yet. We sweep new filings monthly.